Declines in HRZN shares often reflect investor caution regarding credit performance, potential portfolio company non-accruals, and net asset value adjustments within its venture lending portfolio. Because the company lends to development-stage technology and life science enterprises that rely heavily on continuous venture capital funding, any tightening in broader private equity financing environments or shifts in interest rate structures can create market anxiety, driving temporary downward corrections in the stock.